Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta exchanges $291.4 million of 2027 convertible notes for new 2030 notes

Neutral Impact 3 of 5 financing Written later

Sarepta Therapeutics agreed to exchange about $291.4 million of its 1.25% Convertible Senior Notes due 2027 for an equal principal amount of new 4.875% Convertible Senior Notes due 2030, plus about $31.6 million in cash. The new notes were issued on December 18, 2025, and bring the total outstanding 2030 notes to about $893.4 million, which affects the company's debt structure and the terms shareholders hold.

Key points

  • Exchange covers about $291.4 million of 2027 notes, paid with an equal principal amount of 2030 notes plus about $31.6 million in cash
  • New 4.875% Convertible Senior Notes due 2030 were issued December 18, 2025, under the August 28, 2025 indenture
  • Total 4.875% notes due 2030 outstanding after the exchange: about $893.4 million, up from about $602.0 million issued in August 2025
  • Exchange Agreements were entered December 10, 2025, including a trust affiliated with director Michael Chambers

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECDec 19, 2025, 4:34 PM ET
Accession number0001193125-25-326969

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 19, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.